Danaher Corporation $DHR Stock Purchased by Union Savings Bank

Key Points

• Union Savings Bank increased its Danaher holdings by 258.6% in the third quarter, bringing its position to 7,883 shares valued at approximately $1.75 million. Institutional investors collectively own 79.05% of Danaher’s stock.
• Danaher reported quarterly revenue of $6.26 billion and adjusted earnings of $1.94 per share, exceeding analyst expectations, while revenue grew 5.5% year over year. The company also declared a quarterly dividend of $0.40 per share.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $235.41 price target. Danaher’s collaboration with NVIDIA and plans for an AI-powered autonomous laboratory could support longer-term growth in life-science research.

Union Savings Bank raised its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 258.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,883 shares of the conglomerate's stock after buying an additional 5,685 shares during the period. Danaher comprises 0.7% of Union Savings Bank's investment portfolio, making the stock its 24th largest position. Union Savings Bank's holdings in Danaher were worth $1,746,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Main Street Group LTD acquired a new position in shares of Danaher during the 1st quarter valued at $25,000. N.E.W. Advisory Services LLC purchased a new position in Danaher in the 2nd quarter worth approximately $25,000. Marquette Asset Management LLC boosted its holdings in Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate's stock worth $25,000 after acquiring an additional 73 shares during the period. Evolution Wealth Management Inc. lifted its position in shares of Danaher by 208.0% during the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate's stock worth $29,000 after purchasing an additional 104 shares in the last quarter. Finally, Field & Main Bank purchased a new position in shares of Danaher in the second quarter valued at $29,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Up 0.8%

Shares of Danaher stock traded up $1.81 on Wednesday, hitting $224.65. 3,595,884 shares of the company's stock traded hands, compared to its average volume of 4,457,645. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market cap of $157.93 billion, a P/E ratio of 39.90, a PEG ratio of 2.78 and a beta of 0.76. The firm's 50-day moving average is $212.92 and its 200 day moving average is $195.39.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the previous year, the firm earned $0.77 earnings per share. The business's revenue was up 5.5% compared to the same quarter last year. Equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher's dividend payout ratio is 28.42%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a strong earnings-surprise history and currently shows the two indicators—earnings estimate revisions and an Earnings ESP reading—that can signal another quarterly beat. Analysts expect earnings growth in the upcoming report. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: NVIDIA collaboration supports AI strategy: Danaher announced a partnership with NVIDIA to combine its scientific instruments, laboratory automation, workflow software and domain expertise with NVIDIA’s accelerated computing and AI technologies. The goal is to advance autonomous science and speed up scientific discovery, creating a potentially important long-term growth opportunity in life-science research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous laboratory plans: Danaher plans to launch its first AI-powered autonomous laboratory, with commercial-scale operations expected in early 2027. The initiative could improve laboratory productivity and strengthen Danaher’s positioning in AI-enabled drug discovery, though meaningful revenue benefits are likely longer term. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained its $240 price target for DHR, indicating continued confidence in the company’s outlook but no new change in the valuation view. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board expansion: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings impact. Danaher Enhances Board With New Director Appointments

Analyst Ratings Changes

DHR has been the subject of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Danaher from $220.00 to $240.00 and gave the company an "overweight" rating in a report on Monday. Royal Bank Of Canada upped their price objective on shares of Danaher from $215.00 to $250.00 and gave the company an "outperform" rating in a research report on Monday, October 5th. Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 22nd. The Goldman Sachs Group raised their target price on Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a research note on Monday, September 21st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $235.41.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.